Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD)
- PMID: 23775317
- DOI: 10.1007/s10620-013-2743-5
Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD)
Abstract
Aim: Non-alcoholic steatohepatitis (NASH) patients are at increased risk for progression to cirrhosis. The aim of this study was to assess all-cause and liver-specific mortality in a cohort of non-alcoholic fatty liver disease (NAFLD) patients.
Methods: Biopsy-proven NAFLD patients with and without NASH from two historic databases were included. Clinico-demographic information from the time of biopsy was available. Mortality data were obtained from National Death Index-Plus and used for estimating overall and cause-specific mortality. The non-parametric Kaplan-Meier method with log-rank test and multivariate analyses with Cox proportional hazard model were used to compare cohorts.
Results: Two hundred eighty-nine NAFLD patients were included (50.3 ± 14.5 years old, 39.4 % male, 78.6 % Caucasian, 46.0 % obese, 26.0 % diabetic, 5.9 % with family history of liver diseases). Of these, 59.2 % had NASH whereas 40.8 % had non-NASH NAFLD. NASH patients were predominantly female, had higher aspartate aminotranserase, alanine aminotransferase and fasting serum glucose. During follow-up (median 150 months, maximum 342 months), patients with NASH had higher probability of mortality from liver-related causes than non-NASH NAFLD patients (p value = 0.0026). In the entire NAFLD cohort, older age [aHR = 1.07 (95 % CI = 1.05-1.10)] and presence of type II diabetes [aHR = 2.09 (1.39-3.14)] were independent predictors of overall mortality. However, in addition to age [aHR = 1.06 (1.02-1.10)] having histologic NASH [aHR = 9.16 (2.10-9.88)] was found to be an independent predictor of liver-related mortality. Additionally, presence of type II diabetes was associated with liver-related mortality [aHR = 2.19 (1.00-4.81)].
Conclusions: This long-term follow-up of NAFLD patients confirms that NASH patients have higher risk of liver-related mortality than non-NASH. Additionally, patients with NAFLD and type II diabetes are at highest risk for overall and liver-related mortality.
Similar articles
-
Long-term follow-up of patients with nonalcoholic fatty liver.Clin Gastroenterol Hepatol. 2009 Feb;7(2):234-8. doi: 10.1016/j.cgh.2008.11.005. Epub 2008 Nov 7. Clin Gastroenterol Hepatol. 2009. PMID: 19049831
-
Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease.Gastroenterology. 2013 Oct;145(4):782-9.e4. doi: 10.1053/j.gastro.2013.06.057. Epub 2013 Jul 13. Gastroenterology. 2013. PMID: 23860502 Free PMC article.
-
Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.Gastroenterology. 2011 Jan;140(1):124-31. doi: 10.1053/j.gastro.2010.09.038. Epub 2010 Sep 19. Gastroenterology. 2011. PMID: 20858492
-
Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.Cochrane Database Syst Rev. 2013 Dec 27;(12):CD008623. doi: 10.1002/14651858.CD008623.pub2. Cochrane Database Syst Rev. 2013. PMID: 24374462 Review.
-
Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.Curr Vasc Pharmacol. 2020;18(2):172-181. doi: 10.2174/1570161117666190405164313. Curr Vasc Pharmacol. 2020. PMID: 30961499 Review.
Cited by
-
The effects of gut microbiome manipulation on glycemic indices in patients with non-alcoholic fatty liver disease: a comprehensive umbrella review.Nutr Diabetes. 2024 May 10;14(1):25. doi: 10.1038/s41387-024-00281-7. Nutr Diabetes. 2024. PMID: 38729941 Free PMC article. Review.
-
Cardiovascular disease in patients with metabolic dysfunction-associated steatohepatitis compared with metabolic dysfunction-associated steatotic liver disease and other liver diseases: A systematic review.Am Heart J Plus. 2024 Mar 24;41:100386. doi: 10.1016/j.ahjo.2024.100386. eCollection 2024 May. Am Heart J Plus. 2024. PMID: 38623572 Free PMC article. Review.
-
Changing etiology and epidemiology of hepatocellular carcinoma: Asia and worldwide.J Liver Cancer. 2024 Mar;24(1):62-70. doi: 10.17998/jlc.2024.03.13. Epub 2024 Mar 25. J Liver Cancer. 2024. PMID: 38523466 Free PMC article.
-
Global epidemiology of type 2 diabetes in patients with NAFLD or MAFLD: a systematic review and meta-analysis.BMC Med. 2024 Mar 6;22(1):101. doi: 10.1186/s12916-024-03315-0. BMC Med. 2024. PMID: 38448943 Free PMC article.
-
Co-Morbid Hypothyroidism and Liver Dysfunction: A Review.Clin Med Insights Endocrinol Diabetes. 2024 Feb 11;17:11795514241231533. doi: 10.1177/11795514241231533. eCollection 2024. Clin Med Insights Endocrinol Diabetes. 2024. PMID: 38348020 Free PMC article. Review.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical